Product description : Crizotinib is a kinase inhibitor indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive or ROS 1 positive. Crizotinib is the first FDA

Product Features:

Product Name :Crizonix
Generic Name : Crizotinib
Formulation : Capsule
Available Pack Size : 28’s
Available Strengths : 250mg
Registrations : Oncology